Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Marc Simard
University of Maryland Baltimore, Department: Neurosurgery
Should you be removed from our database? Contact us at [email protected]. Read more below.
Remedy Pharmaceuticals
Payment for services (e.g., consulting fees, honoraria, paid authorship)
Remedy Pharmaceuticals' lead product concerns NCCa-ATP channels that acts through antagonism of the type-1 sulfonylurea receptor (SUR1). Dr. Marc Simard is an inventor of the NCCa-ATP channel, and has an equity interest in Remedy Pharmaceuticals
Spinal cord injury, progressive hemorrhagic necrosis and the NC(Ca-ATP) channel
Each year, SCI devastates the lives of thousands of people worldwide. Short of actual prevention, the best hope for reducing the impact of SCI rests with decreasing secondary injury suffered after trauma. Tremendous progress has been made in cell replacement therapies and rehabilitation, but these treatments work best when administered in the context of the smallest possible lesion. Neutrophil invasion into the penumbra is responsible for significant bystander injury, yet effective treatments to ameliorate neutrophil invasion are lacking. The purpose of this proposal is to demonstrate that inhibition of Sur1 can exert a significant salutary effect in SCI due to inhibition of neutrophil invasion.
Filed on June 02, 2016.
Tell us what you know about Marc Simard's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Marc Simard filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Marc Simard | University of Maryland Baltimore | Conflict of Interest | Remedy Pharmaceuticals | >$600,000 |
| Marc Simard | University of Maryland Baltimore | Conflict of Interest | Remedy Pharmaceuticals | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.